Epidemiology of invasive fungal diseases on the basis of autopsy reports
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Invasive fungal diseases (IFDs) are a major cause of morbidity and mortality among immunocompromised patients and cost to health services. They are difficult to prevent, diagnose, and treat. This difficulty in diagnosis leads us to treat them empirically by using several tools, including epidemiological data, non-culture methods and images. Most of the available epidemiological information may not be accurate because we are dealing with a disease that only has an estimated 50% chance of being diagnosed before death. Therefore, autopsy reports become a valuable tool, not only to define the real epidemiology, but also to address the trend in pre-mortem diagnosis, which is the best marker available to prove the efficiency of the research in IFD. This article reviews and analyzes the data on IFD obtained from 11 single-center, multi-center and nationwide autopsy reports published between 2008 and 2013, and also discusses the issues we need to address in order to improve the quality of the epidemiological data on invasive fungal disease obtained from autopsy reports.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, studies of autopsy reports suggest that only 50% of invasive fungal diseases are diagnosed before death [25].”
From Estimation of Direct Healthcare Costs of Fungal Diseases in the United States (2019) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies found that only half of invasive fungal infections are diagnosed before death [38].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trends in the postmortem epidemiology of invasive fungal infections at a University Hospital
Groll, A. H., Shah, P. M., Mentzel, C., Schneider, M., Just-Nuebling, G., & Huebner, K. (1996) · Journal of Infection · doi:10.1016/s0163-4453(96)92700-0 · Cited by 778 · cited 5×
“From 2008 to 2013, 11 single-center, multi-center and nationwide autopsy reports on IFD have been published worldwide in PubMed [1–6,15–19].”
BackgroundInfluentialImaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign
Greene, R. E., Schlamm, H. T., Oestmann, J.-W., Stark, P., Durand, C., Lortholary, O., Wingard, J. R., Herbrecht, R., Ribaud, P., Patterson, T. F., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/509917 · Cited by 594
Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007)
Lortholary, O., Gangneux, J.-P., Sitbon, K., Lebeau, B., de Monbrison, F., Le Strat, Y., Coignard, B., Dromer, F., & Bretagne, S. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03548.x · Cited by 331
Lewis, R. E., Cahyame‐Zuniga, L., Leventakos, K., Chamilos, G., Ben‐Ami, R., Tamboli, P., Tarrand, J., Bodey, G. P., Luna, M., & Kontoyiannis, D. P. (2013) · Mycoses · doi:10.1111/myc.12081 · Cited by 248 · cited 9×
“Microbiological information was used for diagnosis in one study only [6].”
BackgroundMethodResultInfluentialRickerts, V., Mousset, S., Lambrecht, E., Tintelnot, K., Schwerdtfeger, R., Presterl, E., Jacobi, V., Just-Nubling, G., & Bialek, R. (2007) · Clinical Infectious Diseases · doi:10.1086/512812 · Cited by 209 · cited 1×
“The quality of data on IFD obtained from autopsy reports can certainly be improved by addressing the following issues: a) establishing standard procedures for diagnosis (pathology and microbiology or pathology and polymerase chain reaction (PCR) [20] plus clinical information); b) establishing standard inclusion crite…”
BackgroundBurden of aspergillosis-related hospitalizations in the United States
Dasbach, E. J., Davies, G. M., & Teutsch, S. M. (2000) · Clinical Infectious Diseases · doi:10.1086/317487 · Cited by 159
Menzin, J., Meyers, J. L., Friedman, M., Perfect, J. R., Langston, A. A., Danna, R. P., & Papadopoulos, G. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080325 · Cited by 151 · cited 1×
“aspergillosis at 12 weeks of therapy [8]); d) they may require surgery; e) treatments are prolonged (from weeks to months or years); f) the delay of their treatment is associated with an increased mortality rate [9]; g) they may relapse after apparent cure if a subsequent period of immunosuppression occurs (in this ca…”
BackgroundTrends in the postmortem epidemiology of invasive fungal infections at a university hospital
Lehrnbecher, T., Frank, C., Engels, K., Kriener, S., Groll, A. H., & Schwabe, D. (2010) · Journal of Infection · doi:10.1016/j.jinf.2010.06.018 · Cited by 116 · cited 2×
“[15] Aspergillus-like** Candida NA [16] Aspergillus-like (41) Candida (36) NA**”
Sipsas, N. V., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/503844 · Cited by 92 · cited 1×
“aspergillosis at 12 weeks of therapy [8]); d) they may require surgery; e) treatments are prolonged (from weeks to months or years); f) the delay of their treatment is associated with an increased mortality rate [9]; g) they may relapse after apparent cure if a subsequent period of immunosuppression occurs (in this ca…”
BackgroundTrends in the Postmortem Diagnosis of Opportunistic Invasive Fungal Infections in Patients With AIDS
Antinori, S., Nebuloni, M., Magni, C., Fasan, M., Adorni, F., Viola, A., Corbellino, M., Galli, M., Vago, G., Parravicini, C., et al. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcpraae8lz7dtne · Cited by 84 · cited 10×
“Abbreviations AIDS, acquired immunodeficiency syndrome; IFD, invasive fungal disease.”
BackgroundInfluential
Research works printed but not linked: 1
- [21]Schwarze EW Die Bedeutung der Autopsie--heute und morgen Verh Dtsch Ges Pathol 2001 85 118 31 11894389
Cited by
Estimation of Direct Healthcare Costs of Fungal Diseases in the United States
Benedict, K., Jackson, B. R., Chiller, T., & Beer, K. D. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy776 · Cited by 438
“For example, studies of autopsy reports suggest that only 50% of invasive fungal diseases are diagnosed before death [25].”
BackgroundPrevalence and Healthcare Burden of Fungal Infections in the United States, 2018
Rayens, E., & Norris, K. A. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab593 · Cited by 228
“Previous studies found that only half of invasive fungal infections are diagnosed before death [38].”
BackgroundSchelenz, S., Barnes, R. A., Barton, R. C., Cleverley, J. R., Lucas, S. B., Kibbler, C. C., & Denning, D. W. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70006-x · Cited by 190
Johnson, M. D., Lewis, R. E., Dodds Ashley, E. S., Ostrosky-Zeichner, L., Zaoutis, T., Thompson, G. R., Andes, D. R., Walsh, T. J., Pappas, P. G., Cornely, O. A., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa394 · Cited by 172
The burden of serious human fungal infections in Brazil
Giacomazzi, J., Baethgen, L., Carneiro, L. C., Millington, M. A., Denning, D. W., Colombo, A. L., Pasqualotto, A. C., & in association with the LIFE program (2016) · Mycoses · doi:10.1111/myc.12427 · Cited by 164
von Lilienfeld-Toal, M., Wagener, J., Einsele, H., Cornely, O. A., & Kurzai, O. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0271 · Cited by 164
Townsend, R. W., Dietz, A., Hale, C., Akhtar, S., Kowalski, D. L., Lademacher, C., Lasseter, K. C., Pearlman, H., Rammelsberg, D., Schmitt‐Hoffmann, A. H., et al. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.285 · Cited by 121
Economic Burden of Fungal Diseases in the United States
Benedict, K., Whitham, H. K., & Jackson, B. R. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac097 · Cited by 108
“In general, fungal diseases appear to be widely underdetected as a cause of death [13, 14], so our estimates of productivity loss due to premature deaths are underestimated due to low detection and underreporting.”
BackgroundUpdates in Laboratory Diagnostics for Invasive Fungal Infections
Salcedo, D. A. T., & Powers‐Fletcher, M. V. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01487-19 · Cited by 102
The potential role of plant secondary metabolites on antifungal and immunomodulatory effect
Zhou, X., Zeng, M., Huang, F., Qin, G., Song, Z., & Liu, F. (2023) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12601-5 · Cited by 82
“About 6 in 100,000 people are infected with invasive fungi each year, although only one-half of fatal cases are diagnosed prior to death (Dignani 2014).”
Backgroundde Oliveira, H. C., Monteiro, M. C., Rossi, S. A., Pemán, J., Ruiz-Gaitán, A., Mendes-Giannini, M. J. S., Mellado, E., & Zaragoza, O. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00083 · Cited by 70
“Invasive fungal diseases (IFDs) have a high associated mortality rate and economic cost (Dignani, 2014; Drgona et al., 2014).”
BackgroundMucormycosis: Pathogenesis and Pathology
Challa, S. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-0337-1 · Cited by 60
Rahi, M. S., Jindal, V., Pednekar, P., Parekh, J., Gunasekaran, K., Sharma, S., Stender, M., & Jaiyesimi, I. A. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211039050 · Cited by 63
Demographic and Socioeconomic Factors Associated with Fungal Infection Risk, United States, 2019
Rayens, E. A., Rayens, M. K., & Norris, K. A. (2022) · Emerging infectious diseases · doi:10.3201/eid2810.220391 · Cited by 54
“Evidence suggests that only half of invasive fungal infections are diagnosed before patient death (46).”
BackgroundYamazaki, T., Desai, A., Goldwater, R., Han, D., Howieson, C., Akhtar, S., Kowalski, D., Lademacher, C., Pearlman, H., Rammelsberg, D., et al. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.281 · Cited by 42
Application of Mass Spectrometry Technology to Early Diagnosis of Invasive Fungal Infections
Mery, A., Sendid, B., François, N., Cornu, M., Poissy, J., Guerardel, Y., & Poulain, D. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.01655-16 · Cited by 41
Challenges in the Diagnosis of Invasive Fungal Infections in Immunocompromised Hosts
Antinori, S., Corbellino, M., & Parravicini, C. (2018) · Current Fungal Infection Reports · doi:10.1007/s12281-018-0306-0 · Cited by 44
Dantas, K. C., Mauad, T., de André, C. D. S., Bierrenbach, A. L., & Saldiva, P. H. N. (2021) · Scientific Reports · doi:10.1038/s41598-021-83587-1 · Cited by 51
Nanopore Sequencing of the Fungal Intergenic Spacer Sequence as a Potential Rapid Diagnostic Assay
Morrison, G. A., Fu, J., Lee, G. C., Wiederhold, N. P., Cañete-Gibas, C. F., Bunnik, E. M., & Wickes, B. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01972-20 · Cited by 42
“In fact, based on autopsy reports, it has been estimated that 50% of fungal infections may be undiagnosed (6).”
BackgroundCarvalho-Pereira, J., Fernandes, F., Araújo, R., Springer, J., Loeffler, J., Buitrago, M. J., Pais, C., & Sampaio, P. (2020) · Journal of Fungi · doi:10.3390/jof6040308 · Cited by 35
“IFI are associated with mortality rates, ranging from 2% to 60%, depending on the etiology of invasive infection and the type of underlying disease [3], with high hospital costs [4,5].”
BackgroundMucormycosis and COVID-19-Associated Mucormycosis: Insights of a Deadly but Neglected Mycosis
García-Carnero, L. C., & Mora-Montes, H. M. (2022) · Journal of Fungi · doi:10.3390/jof8050445 · Cited by 34
“Although precise data about the prevalence of this mycosis are unknown, due to the lack of diagnosis, according to epidemiological data of autopsy reports on invasive fungal diseases from 2008 to 2013, the etiological agents of mucormycosis were the fourth most common cause of invasive mycoses in the general populatio…”
BackgroundPowers, C. N., Satyal, P., Mayo, J. A., McFeeters, H., & McFeeters, R. L. (2019) · Molecules · doi:10.3390/molecules24162868 · Cited by 33
Rizzello, I., Castagnetti, F., Toschi, P. G., Bertaccini, P., Primavera, L., Paolucci, M., Faccioli, L., Spinardi, L., Lewis, R. E., Cavo, M., et al. (2017) · Mycoses · doi:10.1111/myc.12697 · Cited by 25
Naqvi, S. A. H., Abbas, A., Hasnain, A., Bilal, Z., Hakim, F., Shabbir, M., Amin, A., & Iqbal, M. U. (2025) · Archives of Microbiology · doi:10.1007/s00203-025-04392-2 · Cited by 32
“In clinical contexts, HTS and PCR-based assays are critical for studying invasive fungal diseases (IFDs) such as those caused by Candida spp. and Aspergillus spp. by enabling species identification, genetic diversity analysis, and antifungal resistance profiling during outbreaks (Dignani 2014 ).”
Yang, N., Zhang, L., & Feng, S. (2023) · Journal of Fungi · doi:10.3390/jof9050592 · Cited by 27
Invasive fungal disease in university hospital: a PCR-based study of autopsy cases.
Ruangritchankul, K., Chindamporn, A., Worasilchai, N., Poumsuk, U., Keelawat, S., & Bychkov, A. (2015) · PubMed · Cited by 27
Pathogenesis and Pathology of Invasive Aspergillosis
Challa, S. (2018) · Current Fungal Infection Reports · doi:10.1007/s12281-018-0310-4 · Cited by 28
Wang, W., Li, M., Fan, P., Wang, H., Cai, J., Wang, K., Zhang, T., Xiao, Z., Yan, J., Chen, C., et al. (2022) · Mycoses · doi:10.1111/myc.13540 · Cited by 21
“In contrast, patients with any of the following criteria were excluded: (1) a possible or probable diagnosis of IPA; (2) a history of IPA prior to pathological diagnosis or chronic cavitary pulmonary aspergillosis; (3) tracheobronchial and allergic bronchopulmonary aspergillosis; (4) lung infection caused by other fun…”
MethodResultUniversal digital high-resolution melting for the detection of pulmonary mold infections
Goshia, T., Aralar, A., Wiederhold, N. P., Jenks, J. D., Mehta, S. R., Karmakar, A., Monish, E. S., Sharma, A., Sun, H., Kebadireng, R., et al. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01476-23 · Cited by 23
“Ground truth IMIs have characteristically been very difficult to diagnose before death, with rates of pre-mortem diagnosis ranging from 12% to 60% (4).”
BackgroundHazar, V., Karasu, G., Uygun, V., Öztürk, G., Kılıç, S. Ç., Küpesiz, A., Daloğlu, H., Aksoylar, S., Atay, D., İnce, E., et al. (2018) · Medical Mycology · doi:10.1093/mmy/myy015 · Cited by 20
Luckowitsch, M., Rudolph, H., Bochennek, K., Porto, L., & Lehrnbecher, T. (2021) · Journal of Fungi · doi:10.3390/jof7030168 · Cited by 18
Ashrafuzzaman, M., Razu, M. H., Showva, N. N., Bondhon, T. A., Moniruzzaman, M., Rahman, S. A. R., Rabby, M. R. I., Akter, F., & Khan, M. (2022) · Cellular Microbiology · doi:10.1155/2022/3381162 · Cited by 14
“Invasive fungal illnesses have also posed a life-threatening hazard to people with impaired immune systems because they are difficult to identify, treat, and prevent [85, 86].”
BackgroundOladele, R. O., Osaigbovo, I. I., Ayanlowo, O. O., Otu, A. A., Hoenigl, M., Cornely, O. A., Chakrabarti, A., & Denning, D. W. (2018) · Mycoses · doi:10.1111/myc.12845 · Cited by 15
Prospective on Alkaloids-based sustainable methods to treat fungal pathogens: a comprehensive review
Saket, A., Choudhary, H., Singh, S., Shukla, A. K., & Srinivasan, T. (2025) · Archives of Microbiology · doi:10.1007/s00203-025-04381-5 · Cited by 15
“Although fungal spores are ubiquitous in the environment—making contact with them virtually unavoidable—fungal infections (FIs) are relatively (HAIs), especially in individuals with underlying health conditions (Dignani 2014; Pathakumari et al. 2020).”
Hou, X., Xiao, M., Chen, S. C.-A., Wang, H., Zhang, L., Fan, X., Xu, Z., Cheng, J., Kong, F., Zhao, Y.-P., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154385 · Cited by 12
“Fungi are a major cause of human disease especially in patients with immune compromise and serious underlying disease [1].”
BackgroundCharacteristics of Invasive Pulmonary Fungal Diseases Diagnosed by Pathological Examination
Zhang, D., Li, X., Zhang, J., Wu, J., & Sun, X. (2021) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2021/5944518 · Cited by 11
Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19
Sharma, N., Wani, S. N., Behl, T., Singh, S., Zahoor, I., Sehgal, A., Bhatia, S., Al‐Harrasi, A., Aleya, L., & BUNGAU, S. G. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-24032-2 · Cited by 12
“On the other hand, as per recent global autopsy data, the most prevalent cause of invasive mycotic illness is mucormycosis, after Candidiasis and Aspergillosis, with the increased number of cases observed in adults and children who are less than one year in age (Dignani 2014).”
BackgroundAlkan, A., Büyükaşık, Y., Uzun, Ö., Demır, A. U., & Çöplü, L. (2024) · Medicine · doi:10.1097/md.0000000000039959 · Cited by 10
“[6] On the other hand, the spectrum of infectious fungal pathogens has changed in the last few decades.”
BackgroundИнвазивные грибковые инфекции: пересмотр определений, новое в диагностике по данным EORTC / MSGERC
Bagirova, N. S. (2020) · Malignant tumours · doi:10.18027/2224-5057-2019-10-3s1-39-48 · Cited by 9
Identification of fungal trehalose for the diagnosis of invasive candidiasis by mass spectrometry
Méry, A., Jawhara, S., François, N., Cornu, M., Poissy, J., Martinez‐Esparza, M., Poulain, D., Sendid, B., & Guérardel, Y. (2022) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2022.130083 · Cited by 9
“Introduction Invasive candidiasis (IC) are major life-threatening nosocomial invasive fungal infections with a low survival rate [1,2].”
Backgroundde-Souza-Silva, C. M., Tavares, A. H., Jerônimo, M. S., de Lima, Y. S., Derengowski, L. D. S., Bocca, A. L., & Silva-Pereira, I. (2015) · Mediators of Inflammation · doi:10.1155/2015/605450 · Cited by 9
Mistro, S., Rosa, L., Gomes, B., Miranda, L. A. V. D. O., & Badaró, R. J. D. S. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2016.1202766 · Cited by 9
“The etiology of these infections can vary depending on regional aspects, and Aspergillus and Candida species have been reported as the major pathogenic agents involved [5].”
BackgroundCao, Y., Li, Y., Wang, M., Wu, Y., Shi, S., Wang, C., Gao, Z., Yang, W., Wang, L., & Kang, H. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1658476 · Cited by 7
“…of IFI and limitations in detection technologies, a substantial proportion of IFI remain undiagnosed and untreated in a timely manner, consequently establishing IFI as one of the frequently overlooked causes of mortality in Intensive Care Unit (ICU) (Clancy and Nguyen, 2013; Dignani, 2014).”
Zhang, S., He, Y., Jiang, E., Wei, J., Yang, D., Zhang, R., Zhai, W., Zhang, G., Wang, Z., Zhang, L., et al. (2017) · Future Microbiology · doi:10.2217/fmb-2017-0131 · Cited by 7
Sung, A., Martin, S., Phan, B., Benigno, M., Stephens, J., Chambers, R. B., & Aram, J. A. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s308744 · Cited by 7
Introductory Chapter: Epidemiology of Invasive Fungal Infection - An Overview
Loreto, É. S., & Tondolo, J. S. M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85955 · Cited by 9
“Based on autopsy reports [46], mucormycosis is the third most common cause of invasive fungal infection, after candidiasis and aspergillosis.”
Peng, Y., Yang, J., Li, Z., Chen, S., Tang, X., & Zhou, J. (2022) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2022.103554 · Cited by 6
The burden of serious fungal infections in Azerbaijan
Huseynov, R. M., Javadov, S., Osmanov, A., Khasiyev, S., Valiyeva, S. R., Almammadova, E., & Denning, D. W. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211043969 · Cited by 6
Resistance of filamental fungi in opportunistic mycoses: literature review
Rodrigues, M. C., Araújo, W. A. F., de Oliveira, I. M., Lana, D. F. D., & Carneiro, G. K. M. (2022) · Research Society and Development · doi:10.33448/rsd-v11i4.26198 · Cited by 6
“…of opportunistic fungal infections has increased concomitantly with the emergence of strains resistant to antifungal therapy, and the use of empirical and prophylactic treatments in neutropenic patients is one of the main factors related to the emergence of resistant species (Dignani, 2014).”
BackgroundInfluentialYağmur, G., Sav, H., Ziyade, N., Elgörmüş, N., Şen, S., Bilgi, E. A., Atan, Y., Büyük, Y., & Kiraz, N. (2016) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13089 · Cited by 6
Schmidt, S., Schwerk, C., Schroten, H., Ishikawa, H., Schubert, R., Lehrnbecher, T., & Rudolph, H. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00644-x · Cited by 4
“Autopsy studies demonstrated a significant increase of IFD over the last decades, with Aspergillus spp. and Candida spp. as the leading pathogens [2–4].”
In the flow of molecular miniaturized fungal diagnosis
Zolotareva, M., Cascalheira, F., Caneiras, C. S. G., Bárbara, C., Caetano, D. M., & Teixeira, M. C. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.06.010 · Cited by 4
Сергеевич, К. И., Климко, Н. Н., Ermakova, V. Y., & Сергеевна, К. В. (2019) · Oncohematology · doi:10.17650/1818-8346-2019-14-1-49-59 · Cited by 4
Sachdeva, M., Malik, M., Pradhan, P., Kaur, K., Dogra, S., & Mathew, J. L. (2024) · Mycoses · doi:10.1111/myc.13722 · Cited by 3
Fungal Infections and Social Determinants of Health: Using Data to Identify Disparities
Williams, S., Benedict, K., & Toda, M. (2024) · Current Fungal Infection Reports · doi:10.1007/s12281-024-00494-4 · Cited by 5
“[26, 27].”
Treatment of invasive fungal disease: A case report
Xiao, X., Wu, J., & Xu, Y. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i16.2374 · Cited by 3
Challa, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-06088-6_8 · Cited by 3
Cabezas-Quintario, M. A., Guerrero, C., Gomez, P., & Pérez‐Fernández, E. (2016) · Revista Española de Patología · doi:10.1016/j.patol.2016.01.007 · Cited by 3
Fungal DNA‐barcoding on a chip: Magnetoresistive biosensors for yeast infection diagnosis
Zolotareva, M., Cascalheira, F., Afonso, R., Corado, M., Martins, A., Caneiras, C. S. G., Bárbara, C., Teixeira, M. C., & Caetano, D. M. (2025) · View · doi:10.1002/viw.20250015 · Cited by 2
Distribution of clinical Candida species and their susceptibility to antifungal agents
Tümer, S., Bayraktar, M., & Öztürk, A. (2021) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000256 · Cited by 2
Amado, M., & Barnes, C. S. (2016) · Fungal biology · doi:10.1007/978-3-319-29137-6_17 · Cited by 2
From bench to bedside - translational approaches in anti-fungal immunology
Seif, M., Häder, A., Löffler, J., & Kurzai, O. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.10.004 · Cited by 2
Сергеевич, К. И., Макарова, Е. В., Ermakova, V. Y., Сергеевна, К. В., & Климко, Н. Н. (2021) · Oncohematology · doi:10.17650/1818-8346-2021-16-2-94-107 · Cited by 1
Epidemiology of Infections Caused by Molds
Cuellar‐Rodríguez, J., & Ostrosky-Zeichner, L. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21006-6 · Cited by 1
Ignatieva, V. I., & Avksentieva, M. V. (2015) · Oncohematology · doi:10.17650/1818-8346-2015-10-2-14-25
Demirçin, S., Dirol, F., Karagöz, Y. M., Aksoy, A., Kırbaş, D. B., & Göral, P. (2017) · The Bulletin of Legal Medicine · doi:10.17986/blm.2017227926
Current and potential treatment options for invasiveCandidainfections
Pyrpasopoulou, A., Iosifidis, Ε., & Roilides, E. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1379392
“However, reported incidence rates should be interpreted with caution because of the aforementioned limitations of surveillance including diagnostic issues and capacity of networks to capture worldwide and longitudinal data [6].”
BackgroundPathogenesis of Mucormycosis: The Spores on a Sail
Tyagi, N., Misra, A., Mishra, H., & Gupta, P. (2022) · University Journal of Dental Sciences · doi:10.21276/ujds.2022.8.2.23
Козак, Д. М., & Овсянникова, Е. Г. (2024) · ASTRAKHAN MEDICAL JOURNAL · doi:10.17021/1992-6499-2024-1-85-92
Li, Y., Zhou, X., Wang, X., Wang, C., Cao, K. X., & Liu, S. (2025) · PubMed Central · doi:10.7499/j.issn.1008-8830.2408034
Fungal Infections of the Central Nervous System: Granulomas and Abscesses
Murthy, J. M. K., Challa, S., Yerasu, M. R., & Parida, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00446-2
Clinical Aspects of Fungal Infections
Loreto, É. S., Tondolo, J. S. M., & Zanette, R. A. (2025) · Fungal biology · doi:10.1007/978-3-032-06014-3_6
Afrose, R., Fatima, Z. H., Zubair, M. Y., Hasan, M., Arif, S. H., Aftab, M., & Ahmad, M. (2025) · IMC Journal of Medical Science · doi:10.55010/imcjms.20.001
Metadata
- Authors
- Dignani, M. C.
- Corresponding author
- Dignani, María Cecilia
- Venue
- F1000Prime Reports
- Publisher
- Faculty Opinions Ltd
- Published
- 2014-09-04
- Volume
- 6
- Pages
- 81-81
- ISSN
- 2051-7599 (ISSN-L)
- PMC
- PMC4166943
- OpenAlex
- W1968954779
- Semantic Scholar
- 7f3948da6d39b2c7b04d75ff6c3cf1553d88a6cd
- Cited by
- 73
- References
- 21
- Citations by year
- 2025: 9 · 2024: 6 · 2023: 2 · 2022: 11 · 2021: 8 · 2020: 7 · 2019: 8 · 2018: 5 · 2017: 4 · 2016: 8 · 2015: 5
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc
- Locations
- F1000Prime Reports (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- invasive fungal infections, autopsy reports, epidemiology, immunocompromised patients, antemortem diagnosis, diagnostic accuracy, empirical antifungal therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.